PRECISEU is a Horizon Europe initiative aiming to strengthen interregional innovation ecosystems in personalised medicine, reducing fragmentation and boosting collaboration across territories through a competitive open call for Joint Interregional Projects (JIPs). Projects are expected to have a genuine European/interregional logic (complementary partners, credible innovation pathway, and alignment with personalised medicine priorities). The call funds Innovation Action-like projects focused on deep-tech innovation in personalised medicine, typically TRL 6-8, under two technical topics: advanced therapeutics and health data for personalised medicine (projects may address one or both, if justified). The procedure is single-stage, with proposals submitted in English via the PRECISEU website.

Objective (as defined in the call): to accelerate the development, validation or implementation-readiness of personalised medicine solutions, with an emphasis on accessibility/affordability, stronger regional innovation capacity, Europe's positioning in advanced therapeutics/health data, and interregional knowledge transfer.

• Eligible applicants: legal entities from EU Member States and Horizon Europe Associated Countries (e.g., companies/SMEs, research institutes, universities, hospitals, public administrations, NGOs), with a PIC (validated before Grant Agreement signature) and not in an EU exclusion situation.
• Funding geography: only beneficiaries established in Funding Agency regions can receive PRECISEU financial support; others may participate self-funded.
  • Funding-eligible regions listed: Catalonia (ES), Baden-Württemberg (DE), Nord-Est (RO), Emilia-Romagna (IT), Lithuania (LT), Crete (GR), Castilla-La Mancha (ES), Lazio (IT), Ireland (IE).
• Consortium rules:
• Minimum 3 independent legal entities from 3 different Funding Agency regions; at least 2 of them in 2 different EU Member States.
• At least one SME from a PRECISEU region.
• Only entities from PRECISEU funding regions may coordinate a proposal.
• Consortium may include max. 1 partner from a PRECISEU non-funding region and max. 1 partner from a non-PRECISEU EU/Associated region (self-funded conditions apply).
• Eligible activities: experimental development (typically TRL 6-8) in advanced therapeutics and/or health data; routine market uptake/roll-out/commercial distribution are not eligible.
• Project duration: must fit within the overall window Oct 2026 - Mar 2029 (exact duration justified by the work plan and innovation/regulatory pathway).

In case of interest, please click on 'm'interessa' and we will contact you.